US4666898A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of obesity, diabetes and other symptoms of hypercorticoidism using etiocholanolones
Assignee: Jackson Laboratory
•
Filing: 1984-12-19
•
Granted: 1987-05-19
•
Expires: 2004-12-19
Abstract
Abstract Obesity, diabetes obesity syndromes and associated hypercorticoidism are treated with alpha and/or beta -etiocholanolone.
Inventors
- 👤 Douglas L. Coleman
- 👤 Norman Applezweig
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 15:21
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/56; A61K31/565
Claims Analysis
Total Claims: 29
Claim 1
Independent Claim
43 words
A method of treating a condition selected from the group consisting of obesity, diabetes syndromes, diabetes associated hypercorticoidism and combinations thereof which comprises administering to a mammal in need of such treatment an obesity, diabetes- or diabetes associated hypercortisolism-antagonistic effective amount of 5-β-androstan-3-ol-17-one.
Claim 2
Independent Claim
43 words
A method of treating a condition selected from the group consisting of obesity, diabetes syndromes, diabetes associated hypercorticoidism and combinations thereof which comprises administering to a mammal in need of such treatment an obesity, diabetes- or diabetes associated hypercortisolism-antagonistic effective amount of 5-β-androstan-3-ol-17-one.
Claim 3
Dependent Claim
12 words
The method of claim 1, wherein the administration is oral or parental.
Claim 4
Dependent Claim
10 words
The method of claim 2, wherein said compound is 5-β-androstan-3-α-ol-17-one.
Claim 5
Dependent Claim
10 words
The method of claim 2, wherein said compound is 5-β-androstan-3β-ol-17-one.
Claim 6
Dependent Claim
18 words
The method of claim 1, wherein the amount administered is about 25-2,000 mg. per 70 kilos per day.
Claim 7
Dependent Claim
12 words
The method of claim 5, wherein the amount is about 50-400 mg.
Claim 8
Dependent Claim
14 words
The method of claim 1, wherein said compound is administered in combination with food.
Claim 9
Dependent Claim
20 words
The method of claim 7, wherein said compound is present in an amount up to about 1% of said food.
Claim 10
Dependent Claim
14 words
The method of claim 7, wherein said compound is in finely dispersed powdered form.
Claim 11
Dependent Claim
14 words
The method of claim 1, wherein said compound is in finely dispersed powdered form.
Claim 12
Dependent Claim
15 words
The method of claim 1, wherein said compound is a mixture of 5-β-androstan-3α-ol-17-one and 5-β-androstan-3β-ol-17-one.
Claim 13
Independent Claim
17 words
A method of treating obesity comprising administering to a mammal an obesity antagonistic effective amount of 5-β-androstan-3-ol-17-one.
Claim 14
Independent Claim
17 words
A method of treating obesity comprising administering to a mammal an obesity antagonistic effective amount of 5-β-androstan-3-ol-17-one.
Claim 15
Dependent Claim
10 words
The method of claim 12, wherein said compound is 5-β-androstan-3α-ol-17-one.
Claim 16
Dependent Claim
10 words
The method of claim 12, wherein said compound is 5-β-androstan-3β-ol-17-one.
Claim 17
Dependent Claim
18 words
The method of claim 12, wherein the amount administered is about 25-2,000 mg. per 70 kilos per day.
Claim 18
Dependent Claim
11 words
The method of claim 15, wherein the amount is 50-400 mg.
Claim 19
Dependent Claim
39 words
A composition for the treatment of a condition selected from the group consisting of obesity, diabetes syndromes, diabetes associated hypercorticoidism and combinations thereof comprising food having dispersed therein an obesity-, diabetes- or diabetes associated-hypercorticoidism antagonistic effective amount of 5-β-androstan-3-ol-17-one.
Claim 20
Dependent Claim
39 words
A composition for the treatment of a condition selected from the group consisting of obesity, diabetes syndromes, diabetes associated hypercorticoidism and combinations thereof comprising food having dispersed therein an obesity-, diabetes- or diabetes associated-hypercorticoidism antagonistic effective amount of 5-β-androstan-3-ol-17-one.
Claim 21
Dependent Claim
10 words
The composition of claim 17, wherein said compound is 5-β-androstan-3-α-ol-17-one.
Claim 22
Dependent Claim
10 words
The composition of claim 17, wherein said compound is 5-β-androstan-3β-ol-17-one.
Claim 23
Dependent Claim
20 words
The composition of claim 17, wherein said compound is present in an amount up to about 1% of said food.
Claim 24
Independent Claim
17 words
A method of treating diabetes comprising administering to a mammal an obesity antagonistic effective amount of 5-β-androstan-3-ol-17-one.
Claim 25
Independent Claim
17 words
A method of treating diabetes comprising administering to a mammal an obesity antagonistic effective amount of 5-β-androstan-3-ol-17-one.
Claim 26
Dependent Claim
10 words
The method of claim 21 wherein said compound is 5-β-androstan-3-α-ol-17-one.
Claim 27
Dependent Claim
10 words
The method of claim 21 wherein said compound is 5-β-androstan-3β-ol-17-one.
Claim 28
Dependent Claim
16 words
The method of claim 21 wherein the amount administered is about 25-2,000 mg/70 kilos per day.
Claim 29
Dependent Claim
11 words
The method of claim 24 wherein the amount is 50-400 mg.
References Cited (Backward Citations)
US4518595A
Cited
US4507289A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-05-18 | 1990-11-17 | 1991-05-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-05-18 | 1994-11-17 | 1995-05-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-05-18 | 1998-11-17 | 1999-05-19 | $7700.00 | Window Closed / Lapsed |